Uncategorized
Implant not recommended in UK, but to be launched in European market
The fluocinolone acetonide intravitreal implant (Iluvien, Alimera) has not met the UK’s
cost-effectiveness thresholds for treating DME. Alimera has, however, signed an agreement with Quintiles for the
implant’s European launch.